Stock Market & Financial News
INTC vs. PINS: Which Tech Stock Deserves a Spot in Your Portfolio?
Intel's AI-driven turnaround and strong funding edge out Pinterest's ad growth, making it the better portfolio pick for now.
Is the Options Market Predicting a Spike in Kimberly-Clark Stock?
Investors need to pay close attention to KMB stock based on the movements in the options market lately.
AFG Lags Industry, Trades at Premium: Here's How to Play the Stock
American Financial stock gains from new business opportunities, increased exposures, a better renewal rate environment and effective capital deployment.
Down 5.3% in 4 Weeks, Here's Why CenterPoint (CNP) Looks Ripe for a Turnaround
CenterPoint (CNP) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Evertz Technologies Limited (ET:CA) Q2 2026 Earnings Call Transcript
Evertz Technologies Limited ( ET:CA ) Q2 2026 Earnings Call December 10, 2025 5:00 PM EST Company Participants Brian Campbell - Executive Vice-President of Business Development Doug Moore - CFO & Secretary Conference Call Participants Thanos Moschopoulos - BMO Capital Markets Equity Research Robert Young - Canaccord Genuity Corp., Research Division Paul Treiber - RBC Capital Markets, Research Division Presentation Operator Good afternoon, ladies and gentlemen, and welcome to the Evertz Q2 of Fiscal 2026 Conference Call. [Operator Instructions] I would now like to turn the conference over to Brian Campbell, Executive Vice President of Business Development.
Transcontinental Inc. (TCL.A:CA) Q4 2025 Earnings Call Transcript
Transcontinental Inc. ( TCL.A:CA ) Q4 2025 Earnings Call December 11, 2025 8:00 AM EST Company Participants Yan Lapointe - Director of Investor Relations & Treasury Thomas Morin - President & CEO Donald LeCavalier - Executive VP & CFO Conference Call Participants Adam Shine - National Bank Financial, Inc., Research Division Sean Steuart - TD Cowen, Research Division Stephen MacLeod - BMO Capital Markets Equity Research David McFadgen - Cormark Securities Inc., Research Division Presentation Operator Welcome to the TC Transcontinental Fourth Quarter and Fiscal Year 2025 Results Conference Call. [Operator Instructions] As a reminder, this conference is being recorded today, December 11, 2025.
3 Domestic Auto Stocks to Consider Amid Upbeat Demand Outlook
Affordable EVs, new tax incentives and rising tariffs set the stage for renewed momentum across key domestic names like GM, PII and BLBD.
Ciena (CIEN) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Ciena (CIEN) give insight into how the company performed in the quarter ended October 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Core & Main (CNM) Just Overtook the 200-Day Moving Average
After reaching an important support level, Core & Main (CNM) could be a good stock pick from a technical perspective. CNM surpassed resistance at the 200-day moving average, suggesting a long-term bullish trend.
Wall Street Bulls Look Optimistic About Emcor Group (EME): Should You Buy?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Earnings Growth & Price Strength Make CACI International (CACI) a Stock to Watch
The Zacks Focus List offers investors a way to easily find top-rated stocks and build a winning investment portfolio. Here's why you should take advantage.
Wall Street Analysts Think Howmet (HWM) Is a Good Investment: Is It?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Wall Street Analysts See Ross Stores (ROST) as a Buy: Should You Invest?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Wall Street Analysts Look Bullish on New Gold (NGD): Should You Buy?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Lovesac (LOVE) Reports Q3 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Lovesac (LOVE) give a sense of how its business performed in the quarter ended October 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Alaska Air (ALK) Is Considered a Good Investment by Brokers: Is That True?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Wall Street Bulls Look Optimistic About Carnival (CCL): Should You Buy?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Is It Worth Investing in AudioEye (AEYE) Based on Wall Street's Bullish Views?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Is It Worth Investing in Dutch Bros (BROS) Based on Wall Street's Bullish Views?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Brokers Suggest Investing in Marvell (MRVL): Read This Before Placing a Bet
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Is It Worth Investing in Vital Farms (VITL) Based on Wall Street's Bullish Views?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Enova Plans to Acquire Grasshopper to Gain Digital Banking Infrastructure
Enova International plans to acquire Grasshopper Bancorp and its wholly owned subsidiary Grasshopper Bank to create what it says will be a “stronger, more diversified financial services provider.” The $369 million transaction will combine Enova's consumer and small business online lending capabilities with Grasshopper's digital banking infrastructure, the companies said in a Thursday (Dec.
Centrica set to benefit if UK provides funding to extend life of nuclear reactors
UBS said Centrica PLC (LSE:CNA) has upside potential from a UK government consultation that could extend the life of existing nuclear assets via the Contracts for Difference (CfD) scheme. The UK government yesterday published a consultation on offering CfDs for existing reactors.
Lakeland Is Under Fire But Is Attractive To Speculate On A Recovery
Lakeland Industries, Inc. reported a sharp revenue and margin decline in 3Q26, triggering a 40% stock drop. LAKE's profitability evaporated due to lower sales, especially in fire equipment and industrials, and high fixed costs. Management expects high single-digit revenue growth and 10–12% adjusted EBITDA margins over the next three quarters.
2026 BDC Outlook: Why I'm Steering Clear Of Main Street Capital
Main Street Capital is highly reliable BDC but faces short-term headwinds from likely Fed rate cuts. MAIN trade at premium Price/NAV multiples, reflecting quality but increasing downside risk if spreads compress. The BDC sector may face challenges in the short term, while growth awaits it in the medium term.
Google DeepMind to open AI-powered research lab in UK
Google's AI unit DeepMind said on Thursday it will open its first “automated research lab” in the United Kingdom next year, giving British scientists priority access to some of the world's most advanced AI tools. The lab will use AI and robotics to run experiments, focusing on developing new superconductor materials for medical imaging and next-generation semiconductors.
Astera Labs: Why I See 20% Upside Despite Near-Term Volatility
Astera Labs earns a "Buy" rating after a 40% pullback, presenting a compelling entry amid robust AI infrastructure demand. Q3 results beat expectations, with revenue up 104% YoY and EPS topping consensus; Q4 guidance remains strong and above Street estimates. ALAB's multi-product roadmap and hyperscaler partnerships position it to capture a multi-billion-dollar AI data center opportunity, despite intensifying competition.
Credo: The Vendor AI Giants Can't Replace
Credo shifts from component supplier to reliability architect, with AECs delivering up to 1,000x improved reliability and halving power consumption. AEC revenue grew double digits QoQ and drove a 272% YoY surge, reinforcing Credo's essential role in hyperscale AI clusters. ZeroFlap optics, ALCs, and SerDes for 200G expand a $10B+ TAM while locking in customers through deep system-level integration.
Eli Lilly reports positive Phase 3 trial results for obesity drug retatrutide
Eli Lilly and Co (NYSE:LLY) has reported positive topline results from its Phase 3 TRIUMPH-4 trial evaluating its obesity treatment retatrutide in adults with obesity and knee osteoarthritis. The investigational drug, a once-weekly injectable targeting GLP‑1, GIP, and glucagon receptors, is designed to regulate appetite and metabolism through multiple hormone pathways.
Is LYFT's Impressive Gross Bookings Growth a Sign for Further Upside?
Lyft hits record $4.8 billion in gross bookings as active riders surge and Price Lock performs very well.
